CTLA4 and myocarditis: The incidence of this hazardous event is generally low, and the main risk factor is the combination of anti-CTLA4 and anti-PD1 agents.147,149,150 Johnson et al. reported about two cases of fulminant myocarditis resulting in fatality due to combined therapy with ipilimumab (anti-CTLA4) and nivolumab (anti-PD1).